I think CGB needs to hold a strong suit of cards for the sp to move. An announcement with some "iron" in it for the market to grab hold of.
CGB's Cannabis businesses "may" keep the light on and keep expenditures low, but I dont see them making big dollars (profits) within the next 2 years. With the head scientist and founder of CannTab, Jeff Renwick, passing away, and their latest news of scaling down (possibly), I have restarted my search for other solutions for my back problem.
The Thailand business is the unknown Ace in the hole, or it could be a Joker card in the pack. It is raw material; from my reading, nothing to indicate tablets will be made there. It will be up to the Thai team, I guess.
CGB is stepping up its marketing for the Grassroots and Fusspot range and is now trying to reconnect with shareholders, which is positive news.
As you said, this time tomorrow we should have some news.
@FrankAZ. Explorers explore, and mining producers are the profit makers. Investors make money by trading on announcements with Explorers.
- Forums
- ASX - By Stock
- CGB
- Court Update November 28th 2022 Medcan v CGB
Court Update November 28th 2022 Medcan v CGB, page-44
-
- There are more pages in this discussion • 193 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGB (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online